The Potent and Selective Oral STAT6 Degrader, KT-621, Affects Gene Transcripts in Human Keratinocytes as Effectively as Dupilumab, and Blocks Th2 Inflammation in Atopic Dermatitis and Asthma Mouse Models
SKIN The Journal of Cutaneous Medicine · 10.11.2025 · 9 (6) · s629
DOI: 10.25251/xbb5zx93 ↗Kurz gefasst
Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.11.2025. Verfasst von Amy Wang und 13 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
STAT6 is an essential transcription factor in the IL-4/IL-13 signaling pathways and the central driver of Th2 inflammation in allergic/atopic diseases. Multiple gain of function mutations of STAT6 have been identified to cause severe atopic/allergic diseases in humans. Dupilumab, an injectable monoclonal antibody that blocks IL-4/IL-13 signaling, is an approved therapy for multiple atopic/allergic diseases therefore targeting STAT6 in these diseases is supported by both human genetics and dupilumab’s clinical activity. STAT6 functions through protein-protein and protein-DNA interactions. It has been challenging to selectively and potently inhibit STAT6 with traditional small molecule inhibitors. However, STAT6 is well suited for a novel targeted protein degradation approach, where a simple binding event is sufficient to drive degradation of the protein and fully block its functions.
Zitieren
APA
Wang, A., Yang, B., Yuan, K., Hossain, A., Karnik, R., Shaw, J., Dong, H., Follows, B., Browne, C., Schmidt, R., Sawant, R., Enerson, B., Nivens, C., & Mainolfi, N. (2025). The Potent and Selective Oral STAT6 Degrader, KT-621, Affects Gene Transcripts in Human Keratinocytes as Effectively as Dupilumab, and Blocks Th2 Inflammation in Atopic Dermatitis and Asthma Mouse Models. SKIN The Journal of Cutaneous Medicine, 9(6), s629. https://doi.org/10.25251/xbb5zx93
Vancouver
Wang A, Yang B, Yuan K, Hossain A, Karnik R, Shaw J, et al. The Potent and Selective Oral STAT6 Degrader, KT-621, Affects Gene Transcripts in Human Keratinocytes as Effectively as Dupilumab, and Blocks Th2 Inflammation in Atopic Dermatitis and Asthma Mouse Models. SKIN The Journal of Cutaneous Medicine. 2025;9(6):s629. doi:10.25251/xbb5zx93
BibTeX
@article{Wang2025,
author = {Wang, Amy and Yang, Bin and Yuan, Karen and Hossain, Alamgir and Karnik, Rahul and Shaw, James and Dong, Huijun and Follows, Bruce and Browne, Chris and Schmidt, Ralf and Sawant, Rupa and Enerson, Bradley and Nivens, Chad and Mainolfi, Nello},
title = {The Potent and Selective Oral STAT6 Degrader, KT-621, Affects Gene Transcripts in Human Keratinocytes as Effectively as Dupilumab, and Blocks Th2 Inflammation in Atopic Dermatitis and Asthma Mouse Models},
journal = {SKIN The Journal of Cutaneous Medicine},
year = {2025},
volume = {9},
number = {6},
pages = {s629},
doi = {10.25251/xbb5zx93}
}
EUVIMED